Krsnaa Diagnostics Ltd

Krsnaa Diagnostics has reported its financial results for the quarter ending December 2024, showing a significant year-on-year increase in Profit After Tax to Rs 39.02 crore. However, the company faces challenges with rising interest expenses, a high Debt-Equity Ratio, and a declining Debtors Turnover Ratio.

Krsnaa Diagnostics has recently experienced an evaluation adjustment, reflecting a reassessment of its market position. In Q2 FY24-25, the company reported net sales of Rs 186.34 crore and an operating profit margin of 26.51%. Its low debt-to-equity ratio and consistent growth highlight its financial stability.

Krsnaa Diagnostics has recently experienced a change in evaluation, reflecting its operational performance and market dynamics. The company reported record net sales and operating profit in Q2 FY24-25, showcasing effective cost management and financial stability, while institutional investors increased their stake, indicating growing confidence.

Krsnaa Diagnostics has recently experienced a revision in its score by MarketsMOJO, reflecting changes in its financial evaluation. Despite this adjustment, the company continues to demonstrate strong long-term growth, with impressive operating profit and sales figures. Institutional investor interest is also on the rise, indicating confidence in its market position.

Krsnaa Diagnostics, a leading player in the hospital and healthcare services industry, has seen a positive trend in its stock performance. On November 26, 2024, the stock reached a 52-week high of Rs. 1041.8 and has received a 'Buy' call from MarketsMOJO. Despite a slight dip, the stock is still trading higher than its moving averages and has outperformed the Sensex in the past year. With its strong presence in the industry, the company has potential for long-term growth.

Krsnaa Diagnostics, a smallcap company in the hospital and healthcare services industry, has seen a significant increase in its stock price, reaching a 52-week high of Rs. 995.5 on November 25, 2024. The company has also received a 'Buy' call from MarketsMOJO and has consistently outperformed the sector, making it a promising investment option.

Krsnaa Diagnostics, a leading player in the hospital and healthcare services industry, has seen a surge in its stock price, reaching a 52-week high of Rs. 980 on November 22, 2024. The company has outperformed the sector by 3.49% and has been on a consecutive gain streak for the last 5 days. It is currently trading above its moving averages and has shown an impressive 1-year performance of 54.84% compared to the Sensex's 18.56%. With a 'Buy' call from MarketsMOJO, Krsnaa Diagnostics is a stock to watch out for in the industry.

Krsnaa Diagnostics, a smallcap company in the healthcare industry, has received a 'Buy' rating from MarketsMOJO. This is due to its low Debt to Equity ratio, strong financial performance with high net sales and operating profit, positive technical indicators, attractive valuation, and increasing institutional interest.

Krsnaa Diagnostics, a leading player in the hospital and healthcare services industry, has reached a 52-week high with its stock price hitting Rs. 973 on November 11, 2024. The stock has outperformed the sector and benchmark index, with a 47.26% increase in the past year. Its current call is 'Hold' and it has been on a consecutive gain for the last 5 days, showing a positive trend in its performance.

Krsnaa Diagnostics, a smallcap company in the healthcare industry, has been downgraded to a 'Hold' by MarketsMOJO due to its current financial standing and technical indicators. The company has a low Debt to Equity ratio, steady long-term growth, and attractive valuation. Institutional investors have also shown confidence in the company.

Krsnaa Diagnostics, a leading player in the hospital and healthcare services industry, has gained 7.44% on October 30, 2024, closing at a new 52-week high of Rs. 955.2. The stock has been on a winning streak for the past three days, outperforming the sector by 7.17%. Its positive trend and outperformance against the Sensex make it a promising stock for investors.

Krsnaa Diagnostics, a smallcap company in the hospital and healthcare services industry, has been gaining attention in the stock market. Its stock price reached a 52-week high of Rs. 916.9 on October 30, 2024, and has been outperforming the sector by 3.16%. The company's strong momentum and positive sentiment make it a promising player in the industry.

Krsnaa Diagnostics, a smallcap company in the healthcare industry, reached a 52-week high of Rs. 902.15 on October 29, 2024. It has outperformed the sector by 5.13% and has seen a consecutive gain for the last 2 days. The stock is also trading higher than its moving averages and has shown a 25.63% increase in the past year, indicating strong potential for growth and profitability.

Krsnaa Diagnostics, a smallcap company in the hospital and healthcare services industry, saw a 7.04% increase in its stock on October 29, 2024, reaching a new 52-week high of Rs. 902.15. This caught the attention of MarketsMOJO, who have given a 'Buy' call for the stock. The stock has been on a consecutive gain streak for the last 2 days, outperforming the sector by 6.88%. It is also trading higher than its moving averages, indicating a positive trend. In comparison to the Sensex, Krsnaa Diagnostics has outperformed with a 1-day performance of 6.03% and a 6.19% rise in the last month.

Krsnaa Diagnostics, a smallcap company in the hospital and healthcare services industry, has reported a significant improvement in its financial performance for the quarter ending September 2024. With the highest net sales, operating profit, and PBT in the last five quarters, the company shows positive near-term trends and potential for investors.

Krsnaa Diagnostics, a smallcap company in the hospital and healthcare services industry, has been making headlines in the stock market with its recent 52-week high of Rs. 901.1 and consecutive gains for the last 4 days. The stock has outperformed the sector by 3.43% and has been trading higher than its moving averages. Its strong performance in the past year can be attributed to the surge in demand for healthcare services during the pandemic.